title: Expression of peptidoglycan-associated lipoprotein is required for virulence in the human model of Haemophilus ducreyi infection.
abstract: Haemophilus ducreyi expresses a peptidoglycan-associated lipoprotein (PAL) that exhibits extensive homology to Haemophilus influenzae protein 6. We constructed an isogenic PAL mutant (35000HP-SMS4) by the use of a suicide vector that contains lacZ as a counterselectable marker. H. ducreyi 35000HP-SMS4 and its parent, 35000HP, had similar growth rates in broth and similar lipooligosaccharide profiles. 35000HP-SMS4 formed smaller, more transparent colonies than 35000HP and, unlike its parent, was hypersensitive to antibiotics. Complementation of the mutant in trans restored the parental phenotypes. To test whether expression of PAL is required for virulence, nine human volunteers were experimentally infected. Each subject was inoculated with two doses (41 to 89 CFU) of live 35000HP and one dose of heat-killed bacteria on one arm and with three doses (ranging from 28 to 800 CFU) of live 35000HP-SMS4 on the other arm. Papules developed at similar rates at sites inoculated with the mutant or parent but were significantly smaller at mutant-inoculated sites than at parent-inoculated sites. The pustule formation rate was 72% (95% confidence interval [CI], 46.5 to 90.3%) at 18 parent sites and 11% (95% CI, 2.4 to 29.2%) at 27 mutant sites (P < 0.0001). The rates of recovery of H. ducreyi from surface cultures were 8% (n = 130; 95% CI, 4.3 to 14.6%) for parent-inoculated sites and 0% (n = 120; 95% CI, 0.0 to 2.5%) for mutant-inoculated sites (P < 0.001). H. ducreyi was recovered from six of seven biopsied parent-inoculated sites and from one of three biopsied mutant-inoculated sites. Confocal microscopy confirmed that the bacteria present in a mutant inoculation site pustule lacked a PAL-specific epitope. Although biosafety regulations precluded our testing the complemented mutant in humans, these results suggest that expression of PAL facilitates the ability of H. ducreyi to progress to the pustular stage of disease.
authors.affiliation: Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202-5124, USA.
authors.forename: K R
authors.initials: KR
authors.lastname: Fortney
authors.forename: R S
authors.initials: RS
authors.lastname: Young
authors.forename: M E
authors.initials: ME
authors.lastname: Bauer
authors.forename: B P
authors.initials: BP
authors.lastname: Katz
authors.forename: A F
authors.initials: AF
authors.lastname: Hood
authors.forename: R S
authors.initials: RS
authors.lastname: Munson
authors.forename: S M
authors.initials: SM
authors.lastname: Spinola
mesh_terms: D000328:Adult; D001425:Bacterial Outer Membrane Proteins; D029968:Escherichia coli Proteins; D005260:Female; D006192:Haemophilus Infections / Q000209:etiology*; D006191:Haemophilus ducreyi / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity*; D006801:Humans; D017493:Leukocyte Common Antigens / Q000032:analysis; D008074:Lipoproteins / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D016366:Open Reading Frames; D010457:Peptidoglycan / Q000235:genetics / Q000378:metabolism*; D010641:Phenotype; D011509:Proteoglycans; D014774:Virulence
chemical_list: D001425:Bacterial Outer Membrane Proteins; D029968:Escherichia coli Proteins; C031163:ExcC protein, E coli; D008074:Lipoproteins; D010457:Peptidoglycan; D011509:Proteoglycans; C069988:PplA protein, Legionella pneumophila; D017493:Leukocyte Common Antigens